The condition long known as PCOS has a new name: Polyendocrine Metabolic Ovarian Syndrome, announced today after 14 years of global collaboration between experts and people with lived experience.
Helena Teede, one of the clinicians involved in the effort, said the change was driven by evidence and by patients. "What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated," she said, calling the old name inaccurate.
The renaming matters because the condition affects 1 in 8 women worldwide — more than 170 million people — and the process to rename it drew participation across six continents, with more than 22,000 survey responses and the involvement of more than 50 patient and professional organizations and 56 academic, clinical, and patient organizations.
That scale was deliberate. Organizers said the new name was intended to better reflect the condition's effects on hormones, weight, metabolic health, mental health, skin, and the reproductive system and to reduce the emphasis on ovarian cysts, which researchers found are not increased in people with the condition.
Teede, describing the human cost the old label carried, said: "It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition." She added that while guidelines have improved care, "a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition."
The renaming effort formally began in response to calls that date back to the 1990s and early 2000s and accelerated after the U.S. National Institutes of Health recommended a name change in 2012, saying the label PCOS was a confusing distraction for patients and providers. Over the past 14 years, multiple international workshops brought together patients and multidisciplinary health professionals to build consensus on terminology and intent.
Terhi Piltonen, another contributor to the process, stressed the cultural sensitivity the team sought. "It was essential that the new name was scientifically correct but also considered across diverse cultural contexts to avoid certain reproductive terms that could heighten stigma and be harmful for women in some countries," she said.
The transition to the new name will not be immediate. Organizers plan a three-year roll-out, with full implementation scheduled in the 2028 International Guideline update. That timetable is intended to give professional bodies, health systems and patient groups time to adapt materials, diagnostic criteria and public messaging.
Context matters: sources involved in the effort say the old name contributed to missed diagnoses and inadequate treatment because it emphasized cysts and ovaries rather than the broader, long-term hormonal or endocrine nature of the disorder. The new name was crafted to avoid stigma and to be more culturally appropriate across regions where reproductive language can have different social consequences.
The friction now is practical. Changing textbooks, training, electronic records and public awareness campaigns across countries and specialties is a large administrative task. Even with broad support from more than 50 organizations and the backing of 22,000 survey respondents, implementation will depend on national societies and guideline panels accepting the new terminology on the three-year timetable.
Round Time News covered the development as it unfolded; a previous report detailed the long push for change and the patient-led effort that shaped it (see The most consequential question now is whether renaming will translate into faster diagnosis and better long-term care. If the 2028 guideline update and the three-year transition succeed, clinicians and patients could see a measurable shift in attention from a misnamed symptom to a complex endocrine and metabolic condition that affects more than 170 million people worldwide.
